Activation of the cannabinoid receptor may have use in Systemic Sclerosis « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Activation of the cannabinoid receptor may have use in Systemic Sclerosis

Posted on June 11, 2008 by crimsoncanary

Data presented at EULAR show that treatment of fibroblasts from systemic sclerosis patients with a cannabinoid antagonist (WIN552122) reduces TGFbeta, CTGF and collagen type-I mRNA.

Filed under: Uncategorized | Tagged: agonist, Cannabinoid

« Exenatide improves glycemic control in Type 2 Diabetes at one year Lilly license TransPharmas transdermal Parathyroid Hormone »

Leave a Reply